ArticleJournal of the National Cancer Center2023

Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study.

Nilupai Abudureheiyimu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.